CEFEPIME FOR INJECTION POWDER FOR SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

即購入

ダウンロード 製品の特徴 (SPC)
20-04-2020

有効成分:

CEFEPIME (CEFEPIME HYDROCHLORIDE)

から入手可能:

APOTEX INC

ATCコード:

J01DE01

INN(国際名):

CEFEPIME

投薬量:

2G

医薬品形態:

POWDER FOR SOLUTION

構図:

CEFEPIME (CEFEPIME HYDROCHLORIDE) 2G

投与経路:

INTRAVENOUS

パッケージ内のユニット:

IV:10ML/IV INF.:SEE PM

処方タイプ:

Prescription

治療領域:

FOURTH GENERATION CEPHALOSPORINS

製品概要:

Active ingredient group (AIG) number: 0150504005; AHFS:

認証ステータス:

APPROVED

承認日:

2009-02-16

製品の特徴

                                PRODUCT MONOGRAPH
Cefepime for Injection
(cefepime hydrochloride)
1 g and 2 g cefepime per vial
Orchid Standard
Antibiotic
_Manufactured by: _
ORCHID HEALTHCARE
(A Division of Orchid Chemicals & Pharmaceuticals Ltd.)
Plot No: B3-B6 & B11-B14, SIPCOT Industrial Park,
Irungattukottai- 602 105, Sriperumbudur P.O.,
Kancheepuram District, INDIA.
_Manufactured for: _
APOTEX INC.
150 Signet Drive
Weston, ON, M9L 1T9
DATE OF PREPARATION
April 20, 2020
Control #: 234594
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL
USE...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
5
WARNINGS AND PRECAUTIONS
......................................................................................
5
ADVERSE REACTIONS
........................................................................................................
8
DRUG INTERACTIONS
.......................................................................................................
10
DOSAGE AND ADMINISTRATION
...................................................................................
10
OVERDOSAGE
.....................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 15
STORAGE AND STABILITY
..............................................................................................
19
SPECIAL HANDLING INSTRUCTIONS
............................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 19
PART II: SCIENTIFIC INFORMATION
.........................................................
                                
                                完全なドキュメントを読む
                                
                            

他の言語のドキュメント

製品の特徴 製品の特徴 フランス語 20-04-2020

この製品に関連するアラートを検索